Abbott Labs Earnings on Deck Today

Abbott Laboratories (NYSE:ABT) is expected to report Q4 earnings before the market open on Wednesday, January 25 with a conference call scheduled for 9:00 am ET. Analysts are looking for EPS of $1.44 on revenue of $10.63B.

The consensus range is $1.37-$1.45 for EPS, and $10.39B-$10.87B for revenue, according to First Call. In Q3, the company reported slight better-than-expected EPS and revenue, saying that it expects to have ongoing double-digit EPS growth and high single-digits sales growth.

Specifically, Abbott expects Q4 EPS of $1.43-$1.45 and FY11 EPS of $4.64-$4.66. Looking ahead, the company said it’s well positioned in emerging markets and sees Nutritionals as its strongest business. It also sees its global vascular business to grow in the mid-to-high single digits, and it expects a very promising market for Hepatitis C. Investors will be looking to hear the latest update and any additional details on the Abbott’s expected split into two publicly traded companies. It had said the split will be completed by the end of the year, and it wouldn’t hamper any M&A opportunities.

Abbott should also give an update on Humira, its arthritis drug the company had previously said would be a strong sustainable growth product for a long time. In the past quarter, Abbott received FDA approval for Xience Prime drug eluting stent, a vitro diagnostic test for leukemia, a test for Chagas disease, and a test to detect vitamin D levels.

Meanwhile, the company also announced positive results from its ATLAS study and its ABSORB trial. Abbott was downgraded to Equal Weight at Barclays and Morgan Stanley. Its price was also lowered to $46 from $49 at Citigroup. Despite the negative analyst commentary, Barron’s says the company still looks robust, with the expected breakup to serve as a catalyst for the company.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS), GlaxoSmithKline plc (NYSE:GSK), Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co., Inc. (NYSE:MRK), Medtronic, Inc. (NYSE:MDT), Boston Scientific Corp. (NYSE:BSX), and Sanofi-Aventis SA (NYSE:SNY).

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at